Satish joined Advent in January 2022 after serving as a CEO of BioMotiv, an operating investment fund.
Satish did his postdoctoral research at Whitehead Institute at MIT. Satish was a co-founder and CEO of NeoGenesis (acquired by Schering-Plough, now Merck), Co-founder and President of Verastem (NADAQ: VSTM) and co-founder of Elicio Therapeutics.
He also served as Vice President and Site Head at Schering-Plough in Cambridge, Massachusetts (now Merck), and Vice President and Site Head at Bristol-Myers Squibb.
He obtained a PhD in Biochemistry from Punjab University in India.